CPHD Related Analyst Ratings
-
Craig-Hallum Downgrades Cepheid (CPHD) to Hold
-
Jefferies Assumes / Downgrades Cepheid (CPHD) to Hold
-
Analyst Calls Cepheid (CPHD) Q1 Beat 'Low Quality'
-
Citi Starts Cepheid (CPHD) at Neutral
-
Piper Jaffray Downgrades Cepheid (CPHD) to Neutral
-
BofA/Merrill Lynch Starts Cepheid (CPHD) at Buy
-
Goldman Sachs Downgrades Cepheid (CPHD) to Neutral
-
Mizuho Securities Upgrades Cepheid (CPHD) to Buy
-
Craig-Hallum Starts Cepheid (CPHD) at Buy
-
Cowen Starts Cepheid (CPHD) at Outperform
-
Goldman Says Cephid (CPHD) is 'Oversold'; Likes New Products, L-T Growth Outlook
-
JPMorgan Starts Cepheid (CPHD) at Overweight
-
Cantor Fitzgerald Starts Cepheid (CPHD) at Hold; Strongly Positioned, But...
-
UBS Maintains a 'Buy' on Cepheid (CPHD); Q2 Review
-
Stephens Downgrades Cepheid (CPHD) to Underweight
-
Canaccord Genuity Maintains a 'Buy' on Cepheid (CPHD); Q2 Preview: Consumable Growth is Key
-
ISI Initiates Coverage on 15 Medical Supply Cos.; Top (ICLR) (PKI) (TMO) (HOLX) (A)
-
Credit Suisse Cautious on Life Science Tool Names Into Q2 Results (CPHD) (ILMN) (WAT) (QGEN) (LIFE) (TMO)
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Rolling Out Another Assay
-
UPDATE: UBS Upgrades Cepheid (CPHD) to Buy; Recent Dip Offers Opportunity
-
GARP Research Downgrades Cepheid (CPHD) to Neutral; Walking A Thin Line
-
GARP Research Cuts Cepheid (CPHD) to Neutral
-
GARP Research Of In Defense on Cepheid (CPHD); Franchise Remains Solid Plus Progress In Pipeline
-
UBS Maintains a 'Neutral' on Cepheid (CPHD); Solid Top-Line Eclipsed by Below-Consensus EPS
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Pick Up Shares on Weakness
-
Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
-
Wedbush Downgrades Meridian Biosciences (VIVO) to Underperform; Larger Challenges in Small Hospitals
-
Goldman Sachs Boosts Price Target On Cepheid (CPHD) to $46
-
UBS Maintains a 'Neutral' on Cepheid (CPHD); High Quality Finish to 2011
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Impressive Q4 and Guidance
-
Raymond James Upgrades Cepheid (CPHD) to Outperform
-
RBC Capital Upgrades Cepheid (CPHD) to Outperform
-
Canaccord Genuity on Life Sciences/Biomedical Devices and Services: 2012 Best Ideas: OraSure (OSUR) and Cepheid (CPHD)
-
UBS Adjusts Estimates and Price Target on Cepheid (CPHD); Posts Modest Beat in 3Q
-
Jefferies Maintains a 'Buy' on Cepheid (CPHD); HBDC Program Gaining Momentum; Raising PT
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Best in Class Continues to Perform
-
Raymond James Downgrades Cepheid (CPHD) to Market Perform
-
Goldman Sachs Upgrades Cepheid (CPHD) to Buy
-
Wedbush Adds Cepheid (CPHD) to its Best Ideas List, Reiterates $45 Price Target
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Updating Model and Raising Price Target
-
Jefferies Maintains a 'Buy' Cepheid (CPHD); Running In An Open Field; Raising Forecasts, Target
-
UBS Maintains a 'Neutral' on Cepheid (CPHD); Posts Strong Second Quarter
-
Natixis Bleichroeder Upgrades Cepheid (CPHD) to Buy
-
Wedbush Upgrades Cepheid (CPHD) to Outperform; An Apple-like 2Q11 Beat
-
Canaccord Genuity Reiterates a 'Buy' on Cepheid (CPHD); Lab Interviews Support GeneXpert Outlook
-
Raymond James Starts Cepheid (CPHD) at Outperform
-
Lazard Capital Downgrades Cepheid (CPHD) to Neutral
-
Goldman Sachs Downgrades Cepheid (CPHD) to Neutral
-
Canaccord Genuity on Life Sciences: A Clinical Lab Perspective of C. Difficile Testing
-
Jefferies Boosts Price Target On Cepheid (CPHD) to $35
Back to CPHD Stock Lookup
